StephanieHaleneMD

PubMed

• 115 citations
  m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development.
  Yimeng Gao, Radovan Vasic, Yuanbin Song, Rhea Teng, Chengyang Liu
  Immunity. 2020-06-16
• 551 citations
  Development and function of human innate immune cells in a humanized mouse model
  Anthony Rongvaux, Tim Willinger, Jan Martinek, Till Strowig, Sofia V Gearty
  Nature Biotechnology. 2014-04-01
• 428 citations
  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
  Eunhee Kim, Janine O. Ilagan, Yang Liang, Gerrit M. Daubner, Stanley Chun-Wei Lee
  Cancer Cell. 2015-05-11

Journal Articles

• SRSF2 Mutations Drive Oncogenesis by Activating a Global Program of Aberrant Alternative Splicing in Hematopoietic Cells  
  Radovan Vasic, Stephanie Halene, Nature

Abstracts/Posters

• Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Rel...
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure
  Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Proton Sensor GPR68 Is Essential to Maintain Myeloid Malignancies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018